Loss of function mutations in STK11, encoding the Ser/Thr protein kinase, LKB1 are responsible for the familial hamartoma syndrome, Peutz Jeghers Syndrome (PJS). Importantly, recent studies have revealed sporatic mutations in STK11 in a variety of human cancers, including lung adenocarcinomas. LKB1 phosphorylates and activates AMP dependent protein kinase in response to energy stress and thus plays a key role in energy homeostasis. The hypothesis guiding this proposal is that the LKB1-AMPK signaling axis evolved to limit cell growth under conditions of energy stress and that genetic or epigenetic aberrations, as well as transcriptional and post-transcriptional events that suppress LKBI function, allow tumor cells to override metabolic control mechanisms that normally limit cell growth under energy stress. The overall goal of the proposal is to elucidate the signaling and metabolic network controlled by LKB,1-AMPK and use this information to identify targets for therapeutic intervention in tumors that lack LKB1.
The specific aims are: 1) to utilize technologies developed during the previous granting period to identify druggable downstream targets in the LKB1/AMPK signaling network;2) to utilize mass spec metabolomics to identify metabolic pathways that are altered in cancers that result from loss of LKB1 and, 3) to use genetically engineered mice that develop cancers due to loss of LKBI, in the context of other genetic aberrations observed in human lung cancers, to evaluate drugs or drug combinations, predicted on the basis of in vitro studies in Aims 1 and 2.

Public Health Relevance

The relevance of these studies is that they will provide a rationale for generating clinical trials in which patients with LKB1 mutations are placed on approved or experimental drugs or drug combinations that have been validated based on knowledge of the pathway and evidence for synthetic lethality in an in vivo setting.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA120964-08
Application #
8719040
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
8
Fiscal Year
2014
Total Cost
$263,723
Indirect Cost
$9,781
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Young, Nathan P; Kamireddy, Anwesh; Van Nostrand, Jeanine L et al. (2016) AMPK governs lineage specification through Tfeb-dependent regulation of lysosomes. Genes Dev 30:535-52
Leonard, Paul G; Satani, Nikunj; Maxwell, David et al. (2016) SF2312 is a natural phosphonate inhibitor of enolase. Nat Chem Biol 12:1053-1058
Sumita, Kazutaka; Lo, Yu-Hua; Takeuchi, Koh et al. (2016) The Lipid Kinase PI5P4Kβ Is an Intracellular GTP Sensor for Metabolism and Tumorigenesis. Mol Cell 61:187-98
Nathan, Neera; Tyburczy, Magdalena E; Hamieh, Lana et al. (2016) Nipple Angiofibromas with Loss of TSC2 Are Associated with Tuberous Sclerosis Complex. J Invest Dermatol 136:535-8
Koyama, Shohei; Akbay, Esra A; Li, Yvonne Y et al. (2016) Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 7:10501
Mullarky, Edouard; Lucki, Natasha C; Beheshti Zavareh, Reza et al. (2016) Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers. Proc Natl Acad Sci U S A 113:1778-83
Cox, Andrew G; Tsomides, Allison; Kim, Andrew J et al. (2016) Selenoprotein H is an essential regulator of redox homeostasis that cooperates with p53 in development and tumorigenesis. Proc Natl Acad Sci U S A 113:E5562-71
Li, Ming; Tucker, Lynne D; Asara, John M et al. (2016) Stem-loop binding protein is a multifaceted cellular regulator of HIV-1 replication. J Clin Invest 126:3117-29
Toyama, Erin Quan; Herzig, Sébastien; Courchet, Julien et al. (2016) Metabolism. AMP-activated protein kinase mediates mitochondrial fission in response to energy stress. Science 351:275-81
Ilagan, Erika; Manning, Brendan D (2016) Emerging role of mTOR in the response to cancer therapeutics. Trends Cancer 2:241-251

Showing the most recent 10 out of 229 publications